Medications That Cause Dry Mouth: Complete List and Fixes

Last updated: June 2026 | Reviewed against current ADA guidance, peer-reviewed xerostomia literature, and clinical pharmacology research

You started a new medication and noticed your mouth feels persistently dry. Or you have been on a long-term prescription for blood pressure, allergies, or depression and your dentist keeps finding new cavities in places that were healthy for years. The connection between the two things may not have been explained to you, but it is well-established in the dental and pharmacological literature.

Over 400 drugs list xerostomia as a known side effect. Studies confirm that medication is the most common risk factor for dry mouth, especially in older adults, and that polypharmacy, taking five or more medications simultaneously, compounds the risk substantially. This guide covers the full list of drug classes responsible, the mechanism by which they reduce saliva, and the steps that address the dental consequences.

How Common Is Medication-Induced Dry Mouth?

The scale of the problem is larger than most patients realize. A comprehensive review of the literature consistently identifies medication as the single most frequent cause of dry mouth in adults. In older adult populations specifically, the evidence is unambiguous: a 2026 narrative review published in Frontiers in Dental Medicine reported that medications with anticholinergic burden, as well as many antihypertensive and psychotropic agents, are strongly associated with salivary gland hypofunction and xerostomia. Polypharmacy affects more than 30 to 44% of older adults globally, with even higher rates in those with cardiovascular disease, diabetes, and multiple comorbidities.

A 2025 cross-sectional study published in the Journal of Clinical Medicine (MDPI, September 2025) enrolled 141 middle-aged adults aged 45 to 64 with self-reported xerostomia from anticholinergic medications and objectively confirmed salivary flow reduction in the majority. The study established that intraoral painful aching and elevated anxiety were significantly associated with the severity of medication-induced xerostomia, expanding the understanding of its impact beyond the oral cavity.

A separate peer-reviewed review published in European Psychiatry (Maldonado-Puebla, Murugappan, and Carr, Nova Southeastern University and University of Florida, 2025) confirmed that xerostomia is a frequently reported adverse effect of psychiatric medications specifically, noting prevalence of 80% in antipsychotic users, 44.4% in antidepressant users, and 11.1% in SSRI users. These are not rare edge cases; they represent the experience of a large proportion of the people taking these medication classes.

Why Medications Reduce Saliva: The Anticholinergic Mechanism

Most drug-induced dry mouth shares a common pathway: anticholinergic activity. Salivary secretion is primarily controlled by the parasympathetic nervous system through acetylcholine binding to muscarinic receptors in the salivary glands. When drugs block this binding, the signal that tells salivary glands to produce saliva is suppressed. Reduced signaling equals reduced output.

The European Psychiatry review by Maldonado-Puebla et al. (2025) stated this mechanism directly: anticholinergics and psychotropic medications cause xerostomia by blocking acetylcholine from binding to muscarinic receptors in the salivary glands. This is the same pathway through which many antihistamines, antidepressants, antispasmodics, and bladder medications produce their therapeutic effects: the drying of secretions is often not a side effect so much as the mechanism of action applied in the wrong tissue.

Not all drug-induced dry mouth is purely anticholinergic. Some medications reduce saliva through separate mechanisms:

Diuretics reduce total body fluid volume. By depleting the fluid reservoir the salivary glands draw on, they produce systemic dehydration that manifests as dry mouth among other effects. Antihypertensives including beta-blockers, ACE inhibitors, and centrally acting alpha-agonists (like clonidine) alter autonomic control of the salivary glands or interfere with the nervous signaling that regulates secretion. GLP-1 receptor agonists, as covered in our article on Ozempic and oral health, act on GLP-1 receptors expressed in the salivary glands and may desensitize them over time through a distinct cAMP-beta-arrestin pathway.

The Major Drug Classes That Cause Dry Mouth

The following covers the drug classes most consistently associated with xerostomia, with the specific drugs most commonly cited in clinical literature. This is not an exhaustive list of every medication that can cause dry mouth, but it covers the classes affecting the largest number of patients.

Antidepressants

Antidepressants are among the most common causes of medication-induced dry mouth and one of the most clinically significant because they are often taken long-term. Tricyclic antidepressants (TCAs) such as amitriptyline are particularly strong anticholinergic agents and produce dry mouth frequently. SSRIs including sertraline (Zoloft) and fluoxetine (Prozac) produce lower rates of xerostomia than TCAs but still affect 11% or more of users. SNRIs such as venlafaxine and duloxetine sit between TCAs and SSRIs in terms of anticholinergic burden. Bupropion is also associated with dry mouth through a different mechanism involving dopamine and norepinephrine reuptake. A 2018 meta-analysis published in Progress in Neuro-Psychopharmacology and Biological Psychiatry (cited in GoodRx's clinical review) confirmed the risk of dry mouth across second-generation antidepressants as a class.

Antipsychotics

Antipsychotics carry the highest reported prevalence of xerostomia among psychiatric medications, with one study reporting up to 80% of users affected. Both older first-generation antipsychotics (phenothiazines, butyrophenones) and many second-generation agents have significant anticholinergic activity affecting salivary gland output. Clozapine, notably, produces the opposite effect in some patients (excessive salivation), but this is an exception; most antipsychotics suppress salivation.

Antihistamines

Antihistamines are among the most widely used over-the-counter medications globally and one of the most common causes of dry mouth that patients do not connect to their medication. First-generation antihistamines including diphenhydramine (Benadryl) and chlorphenamine have strong anticholinergic activity and produce significant dry mouth. Second-generation antihistamines including loratadine (Claritin) and cetirizine (Zyrtec) are less anticholinergic but still associated with reduced salivation in a portion of users. Dimenhydrinate (Gravol) and meclizine (motion sickness medications) also carry anticholinergic drying effects. The relevance here is that people taking antihistamines for seasonal allergies may be on them for months at a time, creating sustained salivary suppression that compounds cavity risk.

Diuretics and Blood Pressure Medications

Diuretics, commonly called water pills, are among the most frequently prescribed medications for hypertension and heart failure. Hydrochlorothiazide and furosemide reduce total body fluid, producing dry mouth as a systemic dehydration effect. Beta-blockers (metoprolol, atenolol) alter autonomic nerve signaling to the salivary glands. ACE inhibitors produce dry mouth less commonly. Centrally acting alpha-agonists like clonidine and methyldopa suppress sympathetic outflow and can reduce salivary secretion through central nervous system effects. The 2026 Frontiers in Dental Medicine review confirmed that antihypertensive agents of multiple classes are strongly associated with salivary gland hypofunction.

Muscle Relaxants

Cyclobenzaprine and tizanidine, both commonly prescribed for musculoskeletal pain and spasm, carry anticholinergic activity that suppresses salivation. Cyclobenzaprine in particular has a chemical structure closely related to tricyclic antidepressants and shares their anticholinergic burden. Patients on muscle relaxants for back pain or injury often experience dry mouth as a prominent side effect that their prescriber may not have flagged as significant.

Opioid Analgesics

Opioids including codeine, oxycodone, morphine, and hydrocodone reduce salivary secretion through multiple pathways: direct anticholinergic activity, reduced autonomic stimulation through opioid receptor activation, and dehydration through reduced fluid intake in sedated patients. Dry mouth is a frequently reported complaint in patients on both acute and long-term opioid therapy.

Bladder and Antispasmodic Medications

Medications used for overactive bladder or urinary incontinence, including oxybutynin (Ditropan), tolterodine, solifenacin, and trospium, are specifically designed to have anticholinergic effects on smooth muscle. Since the mechanism is intentional and systemic rather than targeted, it suppresses salivary gland function alongside the bladder effects. Atropine and scopolamine, used for various antispasmodic purposes and motion sickness, have the same mechanism and produce pronounced dry mouth.

Decongestants

Sympathomimetic decongestants including pseudoephedrine and phenylephrine are common in over-the-counter cold and allergy medications. They reduce mucous membrane secretions across the respiratory tract, and this drying effect extends to the salivary glands. Many OTC cold tablets combine a decongestant with an antihistamine, producing a compounded anticholinergic effect that is stronger than either ingredient alone.

Bronchodilators

Inhaled bronchodilators including albuterol and ipratropium can cause oral dryness, particularly when inhaled without a spacer, which concentrates drug deposition in the mouth rather than the lungs. Inhaled corticosteroids contribute to oral dryness and can also promote oral candidiasis (thrush) when salivary antimicrobial function is compromised. Rinsing the mouth with water after inhaler use is a standard recommendation to mitigate both effects.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) represent a newer class of medications with a distinct mechanism for reducing saliva. GLP-1 receptors are expressed in the salivary glands, and prolonged receptor activation from these drugs may desensitize salivary gland responsiveness through beta-arrestin-mediated pathways over time. The ADA Council on Dental Practice has identified dry mouth as the primary oral concern for GLP-1 users. This class is covered in more detail in our article on Ozempic and oral health.

Other Classes Worth Noting

Additional drug classes associated with xerostomia include: lithium (used for bipolar disorder), ADHD medications including amphetamine salts (Adderall) and methylphenidate, benzodiazepines (diazepam, alprazolam), antiparkinson medications (levodopa, biperiden), certain antacids and antidiarrheal agents, and antiretrovirals used in HIV treatment. Chemotherapy and head and neck radiotherapy produce some of the most severe xerostomia, affecting virtually all patients treated, though these are not medication classes in the conventional sense.

What Reduced Saliva Does to Your Teeth

The dental consequences of chronic dry mouth are serious and compound over time. Saliva performs several distinct protective functions that are all compromised simultaneously when salivary flow drops:

Acid buffering is the first loss. After every meal or sugary drink, oral bacteria produce acids that lower mouth pH. Saliva normally neutralizes these acids within 20 minutes through its bicarbonate buffer system. With reduced flow, acids stay on enamel surfaces longer, extending the window of demineralization with every meal.

Remineralization support is the second loss. Saliva delivers calcium, phosphate, and fluoride ions to tooth surfaces, enabling the natural repair of early enamel mineral loss. Without adequate saliva, this remineralization process is compromised, and early demineralization progresses toward cavities instead of reversing.

Antimicrobial defense is the third loss. Saliva contains lysozyme, lactoferrin, secretory IgA, and other antimicrobial proteins that suppress pathogenic bacterial growth. When these are reduced, Streptococcus mutans and other cavity-causing bacteria thrive in the changed environment. A reduced salivary flow rate leads to changes in saliva composition, making it less effective against the acid-producing capacity of the cariogenic oral biofilm.

The clinical result of these three compounding failures is rapid-onset decay: patients who had healthy teeth for decades begin developing multiple new cavities simultaneously, often in unusual locations like the cervical margins (the base of the tooth near the gumline) where saliva protection is most critical and decay is most typical in xerostomic patients.

The Polypharmacy Problem

The risk from medication-induced dry mouth is not simply additive when multiple medications are taken together; it compounds. A 2026 narrative review in Frontiers in Dental Medicine on polypharmacy and oral health in older adults noted that anticholinergic burden from multiple concurrent medications is strongly associated with salivary gland hypofunction, and that this effect worsens with the number of anticholinergic agents taken together.

The "anticholinergic burden" concept matters clinically. A patient taking one antidepressant may have manageable dry mouth. The same patient who also takes an antihistamine for allergies, a bladder medication, and a blood pressure drug may be carrying a combined anticholinergic load that produces severe xerostomia and dramatically accelerated cavity formation. Their GP, cardiologist, urologist, and allergist may each be unaware of what the others have prescribed, and none may have flagged the cumulative oral health risk.

This is particularly significant in older adults, where the intersection of more medications, age-related reductions in baseline salivary function, and reduced dexterity for oral hygiene creates the highest-risk population for medication-related dental damage. The Frontiers review noted that polypharmacy affects 30 to 44% of older adults globally, with even higher rates in those with cardiovascular disease and diabetes, precisely the populations most likely to be on multiple xerogenic drug classes simultaneously.

What to Do About Medication-Induced Dry Mouth

The first and most important step is to tell your dentist which medications you are on and ask them to flag which ones carry xerogenic risk. Many patients do not realize their dry mouth is medication-induced, and dentists who know your full medication list can adjust their preventive approach accordingly, including more frequent visits and earlier intervention when early decay is spotted.

Talk to your prescribing physician about whether alternatives exist. In some cases, medications within the same class have different anticholinergic burdens, and switching to a lower-burden alternative may reduce dry mouth without compromising therapeutic effect. Do not stop or switch medications without medical supervision.

The ADA guidance on xerostomia (available at ada.org) is specific about management: patient education, adequate hydration, lifestyle modifications, and the use of sugar-free gum and mints to stimulate salivary output are explicitly recommended as first-line palliative measures. The ADA lists prescription salivary stimulants (pilocarpine and cevimeline) as options for more severe cases, but notes they carry significant side effect profiles. Avoid alcohol-based mouthwashes, which worsen dryness. Sip water consistently throughout the day rather than relying on thirst cues, which may be blunted.

Why Xylitol Gum Is the Recommended Daily Counter-Measure

The ADA explicitly lists sugar-free chewing gum among the recommended interventions to stimulate salivary output in xerostomia patients. The Mayo Clinic's guidance on dry mouth treatment lists chewing sugar-free gum among its primary recommendations. This is not a fringe suggestion; it is in the mainstream clinical guidance from the leading dental and medical authorities in the US.

Xylitol gum provides more than mechanical stimulation. Chewing any gum after meals stimulates reflex salivation through the chewing motion. Xylitol adds two dimensions on top of that:

First, xylitol's sweetness triggers an additional cephalic-phase salivary response (the sensory anticipatory response that begins before food is even swallowed), increasing the volume of mechanically stimulated saliva. A study on chewing gum for xerostomia published in PMC confirmed that sugar-free chewing gum can stimulate saliva output in xerostomic patients and produce measurable changes in subjective measures of dry mouth within two weeks.

Second, and specifically relevant in the dental context of medication-induced dry mouth, xylitol directly suppresses Streptococcus mutans and reduces periodontopathic bacteria in the oral microbiome. In a mouth where less saliva means less natural antimicrobial defense, an ingredient that actively addresses bacterial populations is doubly valuable. A 2025 systematic review in BMC Oral Health confirmed that xylitol gum significantly reduced S. mutans counts compared to sorbitol gum in 12 of 14 clinical studies reviewed.

Nano-hydroxyapatite adds a remineralization dimension directly relevant to the enamel vulnerability created by reduced saliva. Between meals, when saliva's calcium and phosphate delivery is already compromised by reduced flow, nano-HAp particles at 20 to 100 nanometres can deposit the same mineral that enamel is made of directly into the microporosities of early acid-weakened surfaces. For someone on a long-term medication that reduces their natural remineralization support, this is a meaningful compensatory intervention between brushings and professional visits.

For a deeper look at how saliva protects your teeth and what specifically happens when it is reduced, see our article on how saliva protects your teeth naturally. For the diabetes and oral health connection that is particularly relevant to patients on GLP-1 medications and related drug classes, see our guide on oral health and diabetes.